Cargando…

Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018

This cross-sectional study compares the duration of postapproval trials with that of the pivotal trials used as the basis for the US Food and Drug Administration’s (FDA’s) approval for all indications receiving accelerated approval from 2009-2018.

Detalles Bibliográficos
Autores principales:	Wallach, Joshua D., Ramachandran, Reshma, Bruckner, Till, Ross, Joseph S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579231/ https://www.ncbi.nlm.nih.gov/pubmed/34751764 http://dx.doi.org/10.1001/jamanetworkopen.2021.33601

Ejemplares similares

Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
por: Egilman, Alexander, et al.
Publicado: (2021)

Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval
por: Wallach, Joshua D., et al.
Publicado: (2021)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
por: Skydel, Joshua J., et al.
Publicado: (2022)

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study
por: Wallach, Joshua D., et al.
Publicado: (2018)

Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
por: Pease, Alison M, et al.
Publicado: (2017)

US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera M., et al.
Publicado: (2023)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics
por: Wong, Alissa K., et al.
Publicado: (2023)

Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals
por: Downing, Nicholas S., et al.
Publicado: (2016)

The progress of postapproval clinical studies on Sabin IPV
por: Shi, Li, et al.
Publicado: (2021)

Six‐month outcomes in postapproval HeartMate3 patients: A single‐center US experience
por: Bansal, Aditya, et al.
Publicado: (2022)

Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015
por: MacGregor, Andrea, et al.
Publicado: (2020)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019)

Analysis of US Food and Drug Administration Breast Implant Postapproval Studies Finding an Increased Risk of Diseases and Cancer: Why the Conclusions Are Unreliable
por: Swanson, Eric
Publicado: (2019)

Strengthening postapproval oversight in research ethics committees: Challenges and solutions
por: Shetty, Yashashri Chandrakant, et al.
Publicado: (2023)

Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs
por: Shahid, Izza, et al.
Publicado: (2022)

Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study
por: Dhodapkar, Meera M, et al.
Publicado: (2022)

Results of the combined U.S. multicenter postapproval study of the Nit‐Occlud PDA device for percutaneous closure of patent ductus arteriosus
por: Kobayashi, Daisuke, et al.
Publicado: (2018)

Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020
por: Chen, Siliang, et al.
Publicado: (2021)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration–approved solid tumor therapies, 1995-2021
por: Alabaku, Orges, et al.
Publicado: (2022)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Characteristics of pivotal clinical trials of FDA-approved endovascular devices between 2000 and 2018: An interrupted time series analysis
por: Moon, John T., et al.
Publicado: (2023)

Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019
por: Lythgoe, Mark P., et al.
Publicado: (2022)

The 2018 PhD Grant Recipients of the BSR
por: Nchimi, Alain
Publicado: (2018)

DuraSeal Exact Is a Safe Adjunctive Treatment for Durotomy in Spine: Postapproval Study
por: Kim, Kee D., et al.
Publicado: (2018)

Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases
por: Ismail, Rawa K., et al.
Publicado: (2020)

Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

In Vitro‐to‐In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018
por: Yu, Jingjing, et al.
Publicado: (2020)

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
por: Omae, Kenji, et al.
Publicado: (2022)

Association of Research and Development Investments With Treatment Costs for New Drugs Approved From 2009 to 2018
por: Wouters, Olivier J., et al.
Publicado: (2022)

Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
por: Matsushita, Shunsuke, et al.
Publicado: (2021)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Leadless pacemaker implant in patients with pre‐existing infections: Results from the Micra postapproval registry
por: El‐Chami, Mikhael F., et al.
Publicado: (2019)

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022
por: Luo, Xingxian, et al.
Publicado: (2023)

Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
por: Grischott, Thomas
Publicado: (2020)

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022)

US Supercollider approved
Publicado: (1987)

NIH funding trends to US medical schools from 2009 to 2018
por: Noble, Paige, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u14baglqk5849qg3lepuuiejge